D.E. Shaw & Co
FLGT icon

D.E. Shaw & Co’s Fulgent Genetics FLGT Stock Holding History

D.E. Shaw & Co’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-20,000
Closed -$1.93M – 4826
2021
Q1 		$1.93M Buy
+20,000
New +$2.06M ﹤0.01% 2624

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

D.E. Shaw & Co's FLGT Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Fulgent Genetics (FLGT) stake by 31% in Q1 2026, selling an estimated $4.66M and leaving 486,770 shares worth $7.74M. The position accounts for ﹤0.01% of the portfolio, ranked #1832.

D.E. Shaw & Co first reported a position in FLGT in Q1 2021 and has held it in 18 quarters since. The position peaked at $18.4M in Q4 2025. 157 funds tracked by Wall St. Rank hold FLGT as of Q1 2026.

  • D.E. Shaw & Co held 486,770 shares of Fulgent Genetics worth $7.74M as of Q1 2026.
  • D.E. Shaw & Co sold 214,535 Fulgent Genetics shares in Q1 2026, an estimated $4.66M.
  • Fulgent Genetics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #1832 holding.
  • D.E. Shaw & Co first reported a position in Fulgent Genetics in Q1 2021 and has held it in 18 quarters since.
  • D.E. Shaw & Co's Fulgent Genetics position peaked at $18.4M in Q4 2025.
  • 157 funds tracked by Wall St. Rank held Fulgent Genetics as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.